AU Patent

AU2024279893A1 — Pharmaceutical compositions

Assigned to AstraZeneca AB · Expires 2026-01-22 · 0y expired

What this patent protects

The present specification relates to pharmaceutical compositions comprising Compound [I] ((S)-4- amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4- carboxamide), microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA), …

USPTO Abstract

The present specification relates to pharmaceutical compositions comprising Compound [I] ((S)-4- amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4- carboxamide), microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA), for example tablets with immediate release properties.

Drugs covered by this patent

Patent Metadata

Patent number: AU2024279893A1
Jurisdiction: AU
Classification: —
Expires: 2026-01-22
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.